Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 5;135(11):1285-1298.
doi: 10.1097/CM9.0000000000002181.

Neoantigens in precision cancer immunotherapy: from identification to clinical applications

Qiao Zhang  1   2 , Qingzhu Jia  1 , Jing Zhang  3 , Bo Zhu  1
Affiliations
Review

Neoantigens in precision cancer immunotherapy: from identification to clinical applications

Qiao Zhang et al. Chin Med J (Engl). .

Abstract

Immunotherapies targeting cancer neoantigens are safe, effective, and precise. Neoantigens can be identified mainly by genomic techniques such as next-generation sequencing and high-throughput single-cell sequencing; proteomic techniques such as mass spectrometry; and bioinformatics tools based on high-throughput sequencing data, mass spectrometry data, and biological databases. Neoantigen-related therapies are widely used in clinical practice and include neoantigen vaccines, neoantigen-specific CD8+ and CD4+ T cells, and neoantigen-pulsed dendritic cells. In addition, neoantigens can be used as biomarkers to assess immunotherapy response, resistance, and prognosis. Therapies based on neoantigens are an important and promising branch of cancer immunotherapy. Unremitting efforts are needed to unravel the comprehensive role of neoantigens in anti-tumor immunity and to extend their clinical application. This review aimed to summarize the progress in neoantigen research and to discuss its opportunities and challenges in precision cancer immunotherapy.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
T cell response induced by neoantigens. DC: Dendritic cell; NeoAg: Neoantigen; T: T cell.
Figure 2
Figure 2
The workflow of neoantigen identification. The whole workflow can be divided into five steps. The first step is sequencing of the cancer cells by WGS, WES or RNA-seq, etc. The following steps are variants calling, HLA typing and interactions prediction (interactions among HLA-neoantigen-TCR) based on the sequencing data. The last step is screening the interactions in vitro. ELISA: Enzyme-linked immunosorbent assay; GLIPH: Grouping of lymphocyte interactions by paratope hotspots; HLA: Human leukocyte antigen; INDELs: Short insertions and deletions; RNA-seq: RNA sequencing; SNPs: Single nucleotide polymorphisms; TCR: T cell receptor; WES: Whole exome sequencing; WGS: Whole genome sequencing.
Figure 3
Figure 3
Dynamic neoantigen tracking is used to evaluate the prognosis of cancer patients. This evaluation strategy can be more sensitive and reliable than imaging examination. Individualized gene panels are the key point to make this strategy sensitive and economical. ctDNA: Circulating tumor DNA.
Figure 4
Figure 4
Therapies based on neoantigens. CAR: Chimeric antigen receptor; DC: Dendritic cell.
See this image and copyright information in PMC

References

    1. Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. Lancet 2021; 398:1002–1014. DOI: 10.1016/S0140-6736(21)01206-X. - PubMed
    1. Daher M, Rezvani K. Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer. Cancer Discov 2021; 11:45–58. DOI: 10.1158/2159-8290.CD-20-0556. - PMC - PubMed
    1. Kangas C, Krawczyk E, He B. Oncolytic HSV: underpinnings of tumor susceptibility. Viruses 2021; 13: DOI: 10.3390/v13071408. - PMC - PubMed
    1. Thotathil Z, Jameson MB. Early experience with novel immunomodulators for cancer treatment. Expert Opin Investig Drugs 2007; 16:1391–1403. DOI: 10.1517/13543784.16.9.1391. - PubMed
    1. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl J Med 2012; 366:2455–2465. DOI: 10.1056/NEJMoa1200694. - PMC - PubMed